3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Azacitidine
62
Cyclophosphamide
49
fludarabine phosphate
46
fludarabine
46
Cytarabine
34
Decitabine
32
venetoclax
27
Tacrolimus
21
Specimen Handling
21
Whole-Body Irradiation
19
Mycophenolic Acid
19
Melphalan
19
Filgrastim
19
Busulfan
19
Imatinib Mesylate
18
ruxolitinib
17
Biopsy
15
Dasatinib
14
Antilymphocyte Serum
14
Granulocyte Colony-Stimulating Factor
13
Etoposide
13
Clofarabine
13
Peripheral Blood Stem Cell Transplantation
12
Sirolimus
11
Methotrexate
11
Ipilimumab
11
Injections
11
Thiotepa
10
Stem Cell Transplantation
10
thymoglobulin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
angiotensin I (1-7)
×
Myeloid
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled